替沙基奥仑赛联合帕博利珠单抗治疗复发/难治性弥漫大B细胞淋巴瘤的安全性与疗效:1b期PORTIA研究结果
PORTIA 1b期研究纳入既往≥2线治疗且ECOG体能状态≤1的成人复发/难治性弥漫大B细胞淋巴瘤患者,接受1次替沙基奥仑赛输注,帕博利珠单抗200 mg每21天一次最多6剂,三个队列分别在替沙基奥仑赛输注后第15天(n=4)、第8天(n=4)或前1天(n=4)开始帕博利珠单抗。联合方案可行、安全性可控、无剂量限制性毒性;在替沙基奥仑赛前1天给帕博利珠单抗时观察到初步疗效,但患者样本有限且随访时间短,无法得出确定性结论。
要点
- 替沙基奥仑赛联合帕博利珠单抗可行、安全性可控,未出现剂量限制性毒性。
- 三个队列分别在替沙基奥仑赛输注后第15天(n=4)、第8天(n=4)或前1天(n=4)开始帕博利珠单抗。
- 联合帕博利珠单抗未增强替沙基奥仑赛的细胞扩增,但在替沙基奥仑赛前1天给药时延迟了扩增峰值。
核心结论
- 替沙基奥仑赛联合帕博利珠单抗可行且安全性可控,无剂量限制性毒性;在替沙基奥仑赛前1天给帕博利珠单抗时观察到替沙基奥仑赛的初步疗效,但患者样本有限且随访时间短,无法得出确定性结论。
研究设计与样本
- 1b期PORTIA研究(NCT03630159)纳入既往≥2线治疗且ECOG体能状态≤1的成人复发/难治性弥漫大B细胞淋巴瘤患者。
- 患者第1天接受1次替沙基奥仑赛输注,帕博利珠单抗200 mg每21天一次、最多6剂。
- 三个队列分别在替沙基奥仑赛输注后第15天(n=4)、第8天(n=4)或前1天(n=4)开始帕博利珠单抗,分析包括安全性、疗效、细胞动力学和生物标志物。
主要发现
- 替沙基奥仑赛联合帕博利珠单抗可行且安全性可控,未出现剂量限制性毒性。
- 在替沙基奥仑赛前1天给帕博利珠单抗时观察到替沙基奥仑赛的初步疗效。
- 联合帕博利珠单抗未增强替沙基奥仑赛的细胞扩增,但在替沙基奥仑赛前1天给药时延迟了扩增峰值。
局限性
- 患者样本有限且随访时间短,无法得出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tisagenlecleucel demonstrated high response rates and a manageable safety profile in adults with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) in the JULIET trial. However, lack of response and chimeric antigen receptor (CAR) T-cell exhaustion were observed in patients with programmed cell death protein 1 (PD-1) overexpression. Hence, pembrolizumab, a PD-1 inhibitor, was hypothesized to improve efficacy and cellular expansion of CAR T-cells in vivo. Here, we report the final analysis of the PORTIA trial in adult patients with r/r DLBCL who had ≥2 prior lines of therapy and had an Eastern Cooperative Oncology Group performance status of ≤1. Patients received 1 tisagenlecleucel infusion on day 1. Pembrolizumab (200 mg) was given every 21 days, for up to 6 doses. Three cohorts initiated pembrolizumab on days 15 (n = 4), 8 (n = 4), or -1 (n = 4). Safety, efficacy, cellular kinetics, and biomarker analyses were included. Tisagenlecleucel plus pembrolizumab was feasible and showed a manageable safety profile, without dose-limiting toxicities. Emerging efficacy with tisagenlecleucel was observed when pembrolizumab was given the day before tisagenlecleucel; however, the limited patient sample and short follow-up do not allow for definitive conclusions. Adding pembrolizumab to tisagenlecleucel did not augment the cellular expansion of tisagenlecleucel but delayed peak expansion if given the day before tisagenlecleucel (NCT03630159).
引用
- Jaeger U, Worel N, McGuirk JP, et al. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results. Blood Adv. 2023. PMID: 36044388. doi:10.1182/bloodadvances.2022007779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。